[Vasodilator agents in portal hypertension].
Service d'Hépato-Gastroentérologie, CHU Purpan, Toulouse.
J M
JM
Combis
J P
JP
Vinel
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D006439:Hemodynamics; D006801:Humans; D006975:Hypertension, Portal / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008103:Liver Cirrhosis / Q000150:complications*; D009574:Nitro Compounds / Q000627:therapeutic use*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D014700:Verapamil / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D009574:Nitro Compounds; D012702:Serotonin Antagonists; D014700:Verapamil
Vasodilatateurs et hypertension portale.